Victoria Socha

DocwireNews

Studies among patients aged 21 years and younger have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reductions in HbA1C and BMI. However, data on kidney outcomes in this patient population are limited.To examine the effects of GLP-1 RAs on kidney function in adolescents and young adults with youth-onset type 2 diabetes (YO-T2D), researchers conducted a retrospective analysis of data from patients aged 21 years and younger who were prescribed a GLP-1 RA from January 2015 to May 2024 at the Joslin Diabetes Center in Boston, Massachusetts. Results were reported during the National Kidney Foundation Spring Clinical Meetings 2025.The primary end point of interest was the change in urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) from the time of initiation of the GLP-1 RA to discontinuation or final follow-up. The secondary outcome of interest was change in HbA1c. The Chronic Kidney Disease in Children U25 calculation was used to determine eGFR.Of the 52 patients, 58% were female, 34% were Black, and 16% were Hispanic. Mean age at initiation of GLP-1 RA was 17.3 years, and duration of diabetes was 2 years. A total of 63 GLP-1 RAs were started (37 dulaglutide, 13 semaglutide, 7 liraglutide, and 6 tirzepatide). Forty-one patients had confirmed continuation. The median duration of GLP-1 RA use was 1.4 years.After initiation of GLP-1 RA, there was a decrease in HbA1c from 9.5% to 8.6%; (P=0.04).&nbsp; No statistically significant changes were observed in UACR (9.6 mg/g vs 12.3 mg/g; P=0.11) or eGFR (128 mL/min/1.72 m2 vs 121 mL/min/1.73 m2; P=0.67).In summary, the authors said. &ldquo;Patients with YO-T2D demonstrate early signs of diabetes-related kidney disease with a third experiencing albuminuria. GLP-1 RA reduced HbA1c significantly in patients treated for at least 4 months. Studies with longer follow-up are needed to investigate the role that GLP-1 RA have on kidney outcomes in the youth.&rdquo;Source: Mandel MC, Angus SA, Molina-Guzman J, Rosas SE. Glucagon-like peptide-receptor agonists (GLP-1 RA) and kidney outcomes in patients with youth-onset type 2 diabetes (YO-T2D). Abstract #G-418. Presented at the National Kidney Foundation Spring Clinical Meetings 2025; April 10-13, 2025; Boston, MA. <a href="https://doi.org/10.1053/j.ajkd.2025.02.419" target="_blank" rel="noopener">doi:10.1053/j.ajkd.2025.02.419</a>

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Effect of GLP-1 RA Use on Kidney Outcomes in Young-Onset Type 2 Diabetes

Research explored kidney outcomes among young patients receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe